Related Issuers
by Stephen Carter
Jan 28, 2021 6:31 AM ET
Biogroup EUR1.05bn (up from EUR1bn) 144A/Reg S 2-part. Via JPM (B&D)/BNP/Natixis joint glocos/Citi/CA/DB/GS/HSBC joint books. List Lux. NY law. New term loan size reduced by EUR50m to EUR1.45bn.
- CAB EUR800m (up from EUR750m) sr sec notes due 2028 (7y). NC3 (50%,25%,par). Equity claw: 3y 40%. B2/B-/B+ (negative/stable/stable). Special call: 10% per year the 1st 3 years at 103. IPT mid to high 3s. Px talk: 3.25%-3.50%. Final terms: EUR800m at 3.375%.
- Laboratoire Eimer EUR250m sr notes due 2029 (8y). NC3 (50%,25%,par). Equity claw: 3y 40%. Caa1/CCC/CCC+ (negative/stable/stable). IPT mid 5s. Px talk: 5.00%-5.25%. Final terms: EUR250m at 5.00%.
Did investor call at 10am UKT 01/25. Virtual meetings available through yesterday. Books closed at 10am UKT today. Pricing today. UOP: along with a new EUR1.45bn (down from EUR1.5bn) term loan and EUR80m cash on hand, to repay its existing EUR2.015bn term loan, existing EUR305m 2nd lien debt and existing EUR219m PIK notes. Biz: Leading private medical laboratory testing business in France and Belgium.